Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier deal and intensifying the race for dominance in the lucrative obesity drug market.
Kardashian's moon landing claims spark NASA rebuke, highlighting the need to fact-check viral misinformation.
Fed cuts rates amid policy split, plans balance sheet changes to stabilize liquidity
Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier deal and intensifying the race for dominance in the lucrative obesity drug market.
Kardashian's moon landing claims spark NASA rebuke, highlighting the need to fact-check viral misinformation.
Fed cuts rates amid policy split, plans balance sheet changes to stabilize liquidity